Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509] Technology appraisal guidance Trastuzumab deruxtecan ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Video content above is prompted by the following: • What are the most common adverse events associated with trastuzumab deruxtecan, and how can they be effectively identified and managed to minimize ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

On safety, there was a case of interstitial lung disease (ILD), a side effect that has been seen with other ADCs using Daiichi Sankyo's deruxtecan payload, like AstraZeneca's Enhertu (trastuzumab ...

Game 2 of the finals series will also be played at the MOA Arena on Sunday, March 16. The Tropang Giga and the Gin Kings will have one week before they fight for the championship after wrapping up ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Medscape Gastroenterology, March 11, 2024 Trastuzumab Deruxtecan: Effects in Multiple Cancer Types Dr Maurie Markman discusses the concept of focusing on a particular molecular target and then ...